Panbela Therapeutics (NASDAQ:PBLA) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Panbela Therapeutics (NASDAQ:PBLA) in a report published on Monday morning, Benzinga reports.

Separately, Roth Mkm reaffirmed a buy rating on shares of Panbela Therapeutics in a research report on Wednesday, March 27th.

Panbela Therapeutics Price Performance

Shares of PBLA stock opened at $0.36 on Monday. Panbela Therapeutics has a 1-year low of $0.35 and a 1-year high of $61.40. The stock’s 50-day moving average is $0.40 and its 200 day moving average is $3.73. The company has a market cap of $1.25 million, a P/E ratio of 0.00 and a beta of 1.55.

Panbela Therapeutics (NASDAQ:PBLA) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($1.05). On average, analysts anticipate that Panbela Therapeutics will post -8.38 EPS for the current year.

Panbela Therapeutics Company Profile

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.